Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Total Current Liabilities for 4 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 3.26% to $16.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Dec 2025, up 3.26% year-over-year, with the annual reading at $16.7 million for FY2025, 3.26% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $16.7 million at Orchestra BioMed Holdings, down from $20.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $21.5 million in Q3 2023, with the low at $306538.0 in Q1 2022.
  • Average Total Current Liabilities over 4 years is $12.8 million, with a median of $15.0 million recorded in 2024.
  • Peak annual rise in Total Current Liabilities hit 3833.28% in 2023, while the deepest fall reached 39.63% in 2023.
  • Over 4 years, Total Current Liabilities stood at $18.6 million in 2022, then tumbled by 39.63% to $11.2 million in 2023, then surged by 44.6% to $16.2 million in 2024, then increased by 3.26% to $16.7 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $16.7 million, $20.7 million, and $17.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.